10 Pancreatic : Abraxane + Gemcitabine Improved Overall Survival in phase III Variable ABI- 007/Gemcitabine (N=431) Gemcitabine (N=430) Hazard Ratio HR A+G/G a P-value b Deaths333 (77%)359 (83%) Censored98 (23%)71 (17%) Median (months)8.56.70.720.0000152 95% Confidence Interval 7.89 - 9.536.01 - 7.230.617 – 0.835 Survival Rate (%) at 6 month67%55% 9 month48%36% 12 month35%22% 18 month16%9% 24 month9%4% a 95% CI from stratified Cox model b Stratified log-rank using IVRS strata of region, KPS, and presence of liver mets Confidential – for internal use only 10
{}